Turn Therapeutics Inc. Common Stock (TTRX) - Net Assets
Based on the latest financial reports, Turn Therapeutics Inc. Common Stock (TTRX) has net assets worth $6.12 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.64 Million) and total liabilities ($12.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Turn Therapeutics Inc. Common Stock's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.12 Million |
| % of Total Assets | 32.81% |
| Annual Growth Rate | 638.21% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Turn Therapeutics Inc. Common Stock - Net Assets Trend (2023–2025)
This chart illustrates how Turn Therapeutics Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore Turn Therapeutics Inc. Common Stock operating cash flow efficiency to assess how effectively this company generates cash.
Annual Net Assets for Turn Therapeutics Inc. Common Stock (2023–2025)
The table below shows the annual net assets of Turn Therapeutics Inc. Common Stock from 2023 to 2025. For live valuation and market cap data, see TTRX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $4.69 Million | +2741.42% |
| 2024-12-31 | $-177.43K | -306.87% |
| 2023-12-31 | $85.77K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Turn Therapeutics Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 496249500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.94K | 0.06% |
| Other Components | $27.07 Million | 577.67% |
| Total Equity | $4.69 Million | 100.00% |
Turn Therapeutics Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Turn Therapeutics Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SKY Metals Ltd
AU:SKY
|
$157.35 Million |
|
DAEA TI Co. Ltd
KQ:045390
|
$157.36 Million |
|
Surya Fajar Capital Tbk PT
JK:SFAN
|
$157.38 Million |
|
Hsing Ta Cement Co Ltd
TW:1109
|
$157.46 Million |
|
Ordinary Fully Paid Deferred Settlement
AU:BTRDA
|
$157.16 Million |
|
Intellego Technologies AB
ST:INT
|
$157.08 Million |
|
Shanghai Longyun Advg & Media
SHG:603729
|
$157.07 Million |
|
Bikurey Hasade Holdings Ltd
TA:BKRY
|
$157.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Turn Therapeutics Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -177,432 to 4,686,723, a change of 4,864,155.
- Net loss of 3,194,080 reduced equity.
- Other factors increased equity by 8,058,235.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.19 Million | -68.15% |
| Other Changes | $8.06 Million | +171.94% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Turn Therapeutics Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 17.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 906.65x to 17.21x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $0.01 | $5.87 | x |
| 2024-12-31 | $-0.01 | $5.87 | x |
| 2025-12-31 | $0.34 | $5.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Turn Therapeutics Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -68.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.60x
- Recent ROE (-68.15%) is above the historical average (-913.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | -2672.64% | 0.00% | 0.00x | 23.48x | $-2.30 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.75 Million |
| 2025 | -68.15% | 0.00% | 0.00x | 2.60x | $-3.66 Million |
Industry Comparison
This section compares Turn Therapeutics Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $27,896,581
- Average return on equity (ROE) among peers: -64.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Turn Therapeutics Inc. Common Stock (TTRX) | $6.12 Million | -2672.64% | 2.05x | $157.28 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $67.16 Million | -67.08% | 0.33x | $3.66 Billion |
About Turn Therapeutics Inc. Common Stock
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and de… Read more